Drug sensitivity of human immunodeficiency virus type 1 isolates after ribavirin therapy

Journal of Infectious Diseases

Volumn 175, Issue 1, 1997, Pages 176-178

  Bernier, Richard ^b   Tremblay, Michel ^b   Tsoukas, Christos ^b   Bergeron, Michel G ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS ISOLATION;

EID: 0031032579     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.1.176     Document Type: Article

References (15)

1. Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 1986; 30:201-5.
2. Roberts RB, Laskin OL, Laurence J, et al. Ribavirin pharmacodynamics in high risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987; 42:365-73.
3. McCormick JB, Getchell JP, Mitchell SW, Hicks DR. Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Lancet 1984; 15:1367-9.
4. Fernandez-Lasson R, Patterson JL. Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase. Mol Pharmacol 1990; 38: 766-70.
5. Connor E, Morrison S, Lane J, Oleske J, Sonke RL, Connor J. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 1993; 37:532-9.
6. Roberts RB, Dickinson GM, Heseltine PN, et al. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. J Acquir Immune Defic Syndr 1990; 3:884-92.
7. Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine of HIV replication. Science 1987; 235: 1376-9.
8. Balzarini J, Naesens L, Robins MJ, DeClercq E. Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2′ 3′dideoxyinosine and 2′ 3′-dideoxy-2, 6-diaminopurine riboside. J Acquir Immune Defic Syndr 1990; 3:1140-7.
9. Japour A, Chatis P, Kim S, Crumpacker C. HIV-1 DDI-resistance overcome with combination DDI-ribavirine [abstract PO-A26-0640]. In: Program and abstracts: XI International Conference on AIDS/IV STD World Congress (Berlin). London: Wellcome Foundation, 1993.
10. Richman DD. HIV drug resistance. AIDS Res Hum Retroviruses 1992; 8: 1065-71.
11. Rooke R, Tremblay M, Soudeyns, et al. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 1989; 3:411-5.
12. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1990; 3: 743-6.
13. Bergeron et al. Tolerance of ribavirin in early HIV disease [abstract M.B. 2353]. In: Program and abstracts: VII International Conference on AIDS (Florence, Italy). Rome: Istituto Superiore di Sanita, 1991.
14. Bernier R, Tremblay M. Homologous interference resulting from the presence of defective particles of human immunodeficiency virus type 1. J Virol 1995; 69:291-300.
15. Allen LB, Fingal CM. Failure of type 1 herpesvirus to develop resistance to ribavirin. Antimicrob Agents Chemother 1977; 12:120-1.